Cargando…
Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis
BACKGROUND: Infliximab is a monoclonal antibody that binds and neutralizes circulating tumor necrosis factor-alpha, a key inflammatory cytokine in the pathophysiology of sarcoidosis. Despite the paucity of randomized clinical trials, infliximab is often considered a therapeutic option for refractory...
Autores principales: | Sakkat, Abdullah, Cox, Gerard, Khalidi, Nader, Larche, Maggie, Beattie, Karen, Renzoni, Elisabetta A., Morar, Nilesh, Kouranos, Vasilis, Kolb, Martin, Hambly, Nathan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8905837/ https://www.ncbi.nlm.nih.gov/pubmed/35264154 http://dx.doi.org/10.1186/s12931-022-01971-5 |
Ejemplares similares
-
Infliximab Treatment of Refractory Cardiac Sarcoidosis
por: Asawaeer, Majid, et al.
Publicado: (2020) -
Refractory multisystem sarcoidosis involving pelvic bone responding to infliximab
por: Karjigi, Uma, et al.
Publicado: (2013) -
Comorbidities of sarcoidosis
por: Tana, Claudio, et al.
Publicado: (2022) -
A Case Series of Refractory Cutaneous Sarcoidosis Successfully Treated with Infliximab
por: Tuchinda, Papapit, et al.
Publicado: (2012) -
P249 Predictors of adverse outcome in sarcoidosis complicated by chronic pulmonary aspergillosis
por: Nwankwo, Lisa, et al.
Publicado: (2022)